Therapy in type 2 diabetes: Insulin glargine vs. 2 NPH insulin both in combination with glimepiride
Therapy in type 2 diabetes: Insulin glargine vs. 2 NPH insulin both in combination with glimepiride
复制标题
DOI：
10.1016/j.arcmed.2005.10.015
复制
发表时间：
2006-05-01
影响因子：
7.7
通讯作者：
Jimenez, J
中科院分区：
文献类型：
--
作者：
Eliaschewitz, FG;Calvo, C;Jimenez, J
背景2型糖尿病（T2DM）患者通常无法通过口服降糖药物（OAD）实现充分的血糖控制。胰岛素已被证明可以改善这些患者的血糖控制，但会增加低血糖的风险。本研究比较了甘精胰岛素和NPH胰岛素联合每日一次固定剂量格列美脲治疗在血糖控制和低血糖发生率方面的疗效和安全性。C，方法。在这项在10个拉丁美洲国家进行的开放标签、24周随机试验中，T2DM患者对OAD控制不佳（HbA（1c）≥ 7.5，
Background. Type 2 diabetes (T2DM) patients often fail to achieve adequate glycemic control with oral antidiabetic drugs (OADs). Insulin has been shown to improve glycemic control in these patients but with increased risk of hypoglycemia. This study compared the efficacy and safety of insulin glargine and NPH insulin, both in combination with a once-daily fixed dose of glimepiride, in terms of glycemic control and incidence of hypoglycemia. C,Methods. In this open-label, 24-week randomized trial in ten Latin American countries, T2DM patients poorly controlled on OADs (HbA(1c) >= 7.5 and